Fig. 5From: DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinomaMethy-High UCs have a T cell inflamed and immunosuppressive environment. A The heatmap shows the anticancer immunity activity scores in seven steps across the cancer immunity cycle in UC patients with different methylation subtypes. The activity scores were calculated by TIP software. B, C Violin diagram analyzing the activity status of Step 4 and Step 6. Step 4: trafficking of immune cells to tumors; Step 6: recognition of cancer cells by T cells. P-values were calculated by the Wilcoxon rank test. D, E, F Heatmap displaying the population abundance of tissue-infiltrating immune and stromal cell populations in UC patients with different methylation subtypes. The proportion of infiltrating cells was evaluated by MCPcounter. P-values were calculated by the Wilcoxon rank test. G Expression profiles indicating differences in the anticancer immune response of the two methylation subtypes. APM, antigen presentation machinery, F-TBRS, fibroblast TGFβ response signature. H Immunosuppressive scores in Methy-High and Methy-Low UCB samples. P-values were calculated by two-tailed Student’s t testBack to article page